Bioactive food compounds as adjuvants to breast cancer treatment: vitamin D and omega-3

breast cancer (BC) is the most commonly diagnosed tumor in women and it continues to be the leading cause of cancer death in women. Quality of life decreases significantly during treatment and in the survivors. There is growing evidence linking the intake of certain foods, or their bioactive compoun...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nutrición hospitalaria : organo oficial de la Sociedad Española de Nutrición Parenteral y Enteral 2018-09, Vol.35 (Spec No6), p.64-69
Hauptverfasser: Bermejo, Laura M, Gómez-Candela, Carmen, Dahdouh, Sergio, López-Plaza, Bricia
Format: Artikel
Sprache:spa
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:breast cancer (BC) is the most commonly diagnosed tumor in women and it continues to be the leading cause of cancer death in women. Quality of life decreases significantly during treatment and in the survivors. There is growing evidence linking the intake of certain foods, or their bioactive compounds, with better prognosis of the disease or improvements in physiological parameters that can increase BC patients' quality of life. But there are hardly any reviews to clarify the scientific evidence. gathering and summarizing the available evidence on the effectiveness of the dietary compounds use as coadjuvants for BC treatment. literature search using Pubmed to identify and analyze bioactive compounds as coadjvants for BC treatment. all tested compounds showed antitumor effects in vitro. Vvitamin D decrease risk of bone fracture, and marine lipids may reduce bone resorption and inflammation. there are bioactive compounds with potential to improve the quality of life of women with BC. Vitamin D a marine lipids provide a solid quality scientific evidence. Despite this, more controlled clinical trials are required to establish a direct link between the use of these compounds and the tumor progression or patient survival.
ISSN:1699-5198
DOI:10.20960/nh.2291